Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

soft tissue sarcoma

- PMLiVE

FDA panel fails to back new use for AbbVie’s Humira

Votes 12 to 1 against new use in spondyloarthritis

Biogen Idec building

Biogen Idec’s long-acting beta interferon moves ahead in MS

US and EU accept filings for long-acting multiple sclerosis drug Plegridy

- PMLiVE

Leaked EFPIA memo reveals transparency strategy

Includes plans to use patient groups to support campaign against greater access to trial data

- PMLiVE

FDA approves intravenous Simponi for arthritis treatment

J&J says Simponi Aria will offer less frequent dosing schedule than subcutaneous version

- PMLiVE

EMA names new head of legal service

Stefano Marino is former chair of EFPIA’s trademark committee

- PMLiVE

FDA fast-tracks Elan’s Alzheimer’s drug

Speeds up regulatory process for ELND005 for the treatment of neuropsychiatric symptoms

- PMLiVE

FDA clears first brain test to diagnose ADHD in children

NEBA system available as part of wider clinical assessment

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

- PMLiVE

EMA in firing line as transparency debate widens

Swedish regulator claims EU agency withheld information on drug withdrawn from sale in 2008

- PMLiVE

GSK files combination skin cancer drug in US

Seeks FDA approval for Tafinlar - Mekinist combination in melanoma

AZ target Omthera files blood fat drug in US

FDA submission for Epanova in severe hypertriglyceridemia

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links